A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Latest Information Update: 20 Sep 2022
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation
- Focus Therapeutic Use
- Sponsors EyeGate Pharma; Kiora Pharmaceuticals
- 14 May 2014 New trial record